Key result
Fluvastatin XL 80 mg significantly decreased platelet-activating factor acetyl hydrolase (PAF-AH) activity by 22.8% compared to a 0.4% increase with placebo (P<0.001) in patients with type 2 diabetes.
Why the study?
Does fluvastatin reduce platelet-activating factor acetyl hydrolase (PAF-AH) activity in patients with type 2 diabetes mellitus?
Population
89 patients with type 2 diabetes mellitus (T2DM)
Comparison
Fluvastatin XL 80 mg once-daily for 8 weeks vs Placebo once-daily for 8 weeks
Design
RCT, randomized, double-blind
Follow-up
8 weeks
Authors
Loading...
Fluvastatin lowers PAF-AH activity in T2DM with CAD; leaves open whether this surrogate change improves cardiovascular outcomes.
RCT (n=89)
Double-blind
randomized
Yes
Does fluvastatin reduce platelet-activating factor acetyl hydrolase (PAF-AH) activity in patients with type 2 diabetes mellitus?
Absolute Event Rate: -22.8% vs 0.4%
p-value: p=<0.001
Fluvastatin significantly reduces PAF-AH activity in patients with type 2 diabetes, suggesting an antiatherogenic effect beyond LDL-C and triglyceride lowering.
Winkler et al. (2004) conducted an RCT in Type 2 diabetes mellitus (n=89). Fluvastatin XL vs. Placebo was evaluated on Change in platelet-activating factor acetyl hydrolase (PAF-AH) activity (p=<0.001). Fluvastatin XL 80 mg significantly decreased platelet-activating factor acetyl hydrolase (PAF-AH) activity by 22.8% compared to a 0.4% increase with placebo (P<0.001) in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: